AAFA does not support the changes proposed by USP because we believe they pose a real threat to quality of care. We strongly urge the USP to keep existing guidelines for allergen immunotherapy in place so that millions of patients across the United States can continue to receive the treatment they need.
Are you on Twitter? Join the Asthma and Allergy Foundation of America @AAFANational Wednesday, March 30 at 7 pm for a Spring Allergies Twitter Party! The chat is hosted by the American Academy of Allergy, Asthma & Immunology and Allergic Living. Follow @AAAAI_org and @AllergicLiving and use #allergyready. Post questions about hay fever, pollen troubles and other spring allergy topics. The AAAAI Allergist Panel includes: Dr. Thanai Pongdee @Tpongdee Dr. Matthew Bowdish @MatthewBowdish Dr.
Press Release Contact: Melissa Graham email@example.com (414) 272-6071 Onsite Press Room (March 4-7): (213) 743-6242 POVERTY WIDENS GAP IN CARE FOR ASTHMA AND ALLERGIES Researchers Examine Socioeconomic Disparities at AAAAI Annual Meeting Los Angeles, CA – Socioeconomic disparities are a cause for concern in patients with asthma and allergies, according to several studies presented at the AAAAI Annual Meeting. “We found that patients who have asthma and come from lower income households –...
Proposed regulations introduced by the United States Pharmacopeia (USP) could dramatically limit patient access to allergen immunotherapy (allergy shots). If these new regulations go into effect, allergists would unlikely be able to continue to mix allergen extracts for their patients. The result may limit timelines of allergy shot treatment. The insurance coverage of this treatment may also be restricted. What can I do to prevent these regulations from going into effect? The American...
Join the Asthma and Allergy Foundation of America and the American Academy of Allergy, Asthma & Immunology Thursday, May 5 at 1 pm ET for a #TackleAsthma Twitter chat. Follow @AAFANational and @AAAAI_org and use #TackleAsthma. Experts will answer your questions about exercising with asthma, staying fit and healthy with asthma and more!
There is no cure for asthma, but with the proper diagnosis, medication and an asthma management plan, symptoms can be controlled. When not properly controlled asthma can be deadly. A study being presented at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting called “Where Do Children with Asthma Die? A National Perspective from 2003 to 2014” seeks to address where and which demographics of children are dying because of asthma in the United States.
Researchers analyzed 8 years of data and found that while overall systemic reactions have been declining, people with asthma were most at risk for them. Also no local skin infections or serious infections from injections were reported in 9.5 million injection visits.
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
Join the Asthma and Allergy Foundation of America and the American Academy of Allergy, Asthma & Immunology Wednesday, May 24 at 1 pm EDT for a #AsthmaFit Twitter chat. Follow @AAFANational and @AAAAI_org and use #AsthmaFit. Experts will answer your questions about staying fit and healthy with asthma, managing exercise-induced asthma (EIA) also known as exercise induced bronchoconstriction (EIB) , and more!
Asthma and Allergy Foundation of America Study Shows a Higher Burden of Disease for Patients with Adult- and Late Childhood-Onset Atopic Dermatitis vs. Patients with Early Childhood-Onset Atopic Dermatitis WASHINGTON, D.C. (March 4, 2018) - The Asthma and Allergy Foundation of America (AAFA) today announced data demonstrating a higher burden of disease for patients with adult- and late childhood-onset atopic dermatitis (AD) vs patients with early childhood-onset AD. These results are from...
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .